EXCEED THE SPACE PROVIDED. This application to be the Statistical and Data Management Center (SDMC) for the proposed HIV Prevention Trials Network (HPTN) is submitted by the Fred Hutchinson Cancer Research Center (FHCRC) in response to the National Institute of Allergy and Infectious Disease (NIAID) RFA: AI-98-015, HPTN Leadership Group. The Universityof Washington, School of Public Health and Community Medicine, Department of Biostatistics will be a co-applicant and sub-contractor to the FHCRC. This SDMC application is one component of a three component application comprising the Leadership Group of the HIV Prevention Trials Network (HPTN). Separate applications describe the CORE applicant, Family Health International, Inc., Dr. Willard Gates Jr., PI, and the Central Laboratory applicant, Johns Hopkins University,Dr. Brooks Jackson, PI. The organization of the key scientific leadership components of this new network is shown in Section 1 and includesthe members of the Executive Committee, Prevention Leadership Group, External Advisory Committee, Scientific Working Groups and Protocol Review Committee. The CORE application contains a detailed description of how the HPTN proposes to carry out its scientific agenda. This application takes advantage of the particular strengths provided by both the FHCRC and UW. The FHCRC has several large statistical and data management coordinating centers for multi-site and multi-protocol clinical trial groups. The UW faculty has extensive biostatistical, epidemiological and clinical experience in research in HIV/AIDS and sexually transmitted diseases as well as considerable experience in conducting clinical trials. Drs. Self and Fleming have faculty appointments at both institutions (Dr. Self is Head of the Biostatistics Program at the FHCRC and Dr. Fleming serves as Chairman of the Department of Biostatistics at the UW), as do Drs. Huang and Richardson. With the strong ties that have existed between the two institutions since the FHCRC's establishment in 1972, virtually all FHCRC faculty and many UW faculty hold joint appointments, and thus, from an academic perspective, they can be regarded as the same institution. This application begins with a general background statement relating to the HIV epidemic and prevention efforts, bothunderway and proposed, to reduce the various modes of viral transmission. The balance of the application is specific to the SDMC which, in large measure, draws upon the experience of serving as the Statistical Center for the HIV Network for Prevention Trials (HIVNET) since 1994. The transition from HP/NET to HPTN will be described, as will the procedures andorganizational structures that will be carried forward into the HPTN and those that will be modified to enhance the objectives of the SDMC.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
3U01AI046703-05S2
Application #
7274620
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Matocha, Martha F
Project Start
2000-05-01
Project End
2006-06-30
Budget Start
2005-05-01
Budget End
2006-06-30
Support Year
5
Fiscal Year
2006
Total Cost
$1,536,651
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Adamson, Blythe J S; Fuchs, Jonathan D; Sopher, Carrie J et al. (2015) A new model for catalyzing translational science: the early stage investigator mentored research scholar program in HIV vaccines. Clin Transl Sci 8:166-8
Qin, Li-Xuan; Breeden, Linda; Self, Steven G (2014) Finding gene clusters for a replicated time course study. BMC Res Notes 7:60
Frey, Sharon E; Peiperl, Laurence; McElrath, M Juliana et al. (2014) Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participants. Clin Vaccine Immunol 21:1589-99
Wecker, M; Gilbert, P; Russell, N et al. (2012) Phase I safety and immunogenicity evaluations of an alphavirus replicon HIV-1 subtype C gag vaccine in healthy HIV-1-uninfected adults. Clin Vaccine Immunol 19:1651-60
Keefer, Michael C; Frey, Sharon E; Elizaga, Marnie et al. (2011) A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects. Vaccine 29:1948-58
Li, Fusheng; Finnefrock, Adam C; Dubey, Sheri A et al. (2011) Mapping HIV-1 vaccine induced T-cell responses: bias towards less-conserved regions and potential impact on vaccine efficacy in the Step study. PLoS One 6:e20479
Churchyard, Gavin J; Morgan, Cecilia; Adams, Elizabeth et al. (2011) A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204). PLoS One 6:e21225
Barnabas, Ruanne V; Wasserheit, Judith N; Huang, Yunda et al. (2011) Impact of herpes simplex virus type 2 on HIV-1 acquisition and progression in an HIV vaccine trial (the Step study). J Acquir Immune Defic Syndr 57:238-44
Cooper, Cristine J; Metch, Barbara; Dragavon, Joan et al. (2010) Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients. JAMA 304:275-83
Li, Fusheng; Gilbert, Peter B; Self, Steve G (2007) Identification of cross-neutralization determinants by GAP analysis: a mutational behavior approach. Curr HIV Res 5:87-96

Showing the most recent 10 out of 30 publications